



Kebilidi™ Gene Therapy Treatment Centers

ETS Program Reference Guide

Emerging Therapy Solutions® (ETS) helps reinsurance and stop-loss payers, health plans, HMOs, and self-funded employers, along with third-party administrators and brokers, manage the risk associated with high-cost therapies for rare and complex conditions.

Programs listed here are qualified treatment centers (QTCs) for which ETS either may have contracted rates in place or may have access to rates through single case agreements for **Kebilidi** (eladocagene exuparvovec-tneq; PTC-AADC) which is approved to **aromatic L–amino acid decarboxylase (AADC) deficiency**.

For assistance with your member referral or for more information, contact ETS at 877-445-4822 or by email at clientservices@emergingtherapies.com.

▼ Denotes facilities that currently have cellular therapy rates in place with ETS.

State	City	Program Listing
Massachusetts	Boston	Boston Children’s Hospital
Texas	Houston	Texas Children’s Hospital ▼

© 2025 Emerging Therapy Solutions, Inc. All Rights Reserved. AP-11235. ETS is a trademark of Emerging Therapy Solutions, Inc. All other trademarks referenced herein are the property of their respective owners. The information provided here is believed to be accurate as of the listed document production date and is based on information currently available to us. Because facility and program changes may occur, please confirm details with our ETS clinical consultants at 877-445-4822 or clientservices@emergingtherapies.com. Please note that coverage for any indicated services is subject to applicable plan documents.
11/7/2025